Cytoprotective therapy of gastric ulcers : a controlled clinical evaluation of triletide versus carbenoxolone
Two parallel groups, each of 10 out-patients with endoscopically confirmed benign gastric ulcer, were randomly assigned to receive either 1.5 g/day of triletide, a new tripeptide shown to increase the synthesis of gastroduodenal mucus and to antagonize thromboxane A2, or 0.3 g/day of carbenoxolone....
| Veröffentlicht in: | Pharmatherapeutica. - 1985. - 4(1985), 3 Spec No vom: 15., Seite 166-70 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
1985
|
| Zugriff auf das übergeordnete Werk: | Pharmatherapeutica |
| Schlagworte: | Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Antacids Anti-Ulcer Agents Oligopeptides triletide 50Q6LI773L Carbenoxolone mehr... |